Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided consolidated earnings guidance for the six months ended June 30, 2024. For the period, the company expects Net profit attributable to shareholders of the listed company of Earnings: RMB 642.28 million to RMB 734.82 million Increase as compared with the corresponding period: 420.70% to 495.72% against Earnings: RMB 123.35 million Corresponding period of last year. Net profit after non-recurring profit or loss of Earnings: RMB 308.07 million to RMB 400.61 million Increase as compared with the corresponding period: 286.96% to 403.20% against Earnings: RMB 79.61 million Corresponding period of last year.

Basic earnings per Share of Earnings: RMB 0.4377 per share to RMB 0.5008 per share against Earnings: RMB 0.0841 per share Corresponding period of last year.